Smallpox vaccine based on live, replicating vaccinia virus (VACV) is associated with several potentially serious and deadly complications. Consequently, a new generation of vaccine based on non-replicating Modified vaccinia virus Ankara (MVA) has been under clinical development. MVA seems to induce good immune responses in blood tests, but it is impossible to test its efficacy in vivo in human. One of the serious complications of the replicating vaccine is eczema vaccinatum (EV) occurring in individuals with atopic dermatitis (AD), thus excluding them from all preventive vaccination schemes. In this study, we first characterized and compared development of eczema vaccinatum in different mouse strains. Nc/Nga, Balb/c and C57Bl/6J mice were epicutaneously sensitized with ovalbumin (OVA) or saline control to induce signs of atopic dermatitis and subsequently trans-dermally (t.d.) immunized with VACV strain Western Reserve (WR). Large primary lesions occurred in both mock- and OVA-sensitized Nc/Nga mice, while they remained small in Balb/c and C57Bl/6J mice. Satellite lesions developed in both mock- and OVA-sensitized Nc/Nga and in OVA-sensitized Balb/c mice with the rate 40-50%. Presence of mastocytes and eosinophils was the highest in Nc/Nga mice. Consequently, we have chosen Nc/Nga mice as a model of AD/EV and tested efficacy of MVA and Dryvax vaccinations against a lethal intra-nasal (i.n.) challenge with WR, the surrogate of smallpox. Inoculation of MVA intra-muscularly (i.m.) or t.d. resulted in no lesions, while inoculation of Dryvax t.d. yielded large primary and many satellite lesions similar to WR. Eighty three and 92% of mice vaccinated with a single dose of MVA i.m. or t.d., respectively, survived a lethal i.n. challenge with WR without any serious illness, while all Dryvax-vaccinated animals survived. This is the first formal prove of protective immunity against a lethal poxvirus challenge induced by vaccination with MVA in an atopic organism.

Department of Clinical and Transplant Pathology Institute for Clinical and Experimental Medicine Videnska 9 140 21 Prague 4 Czech Republic

Department of Immunology and Microbiology 1st Medical Faculty Charles University Studnickova 7 128 00 Prague 2 Czech Republic

See more in PubMed

Artenstein AW (2008) New generation smallpox vaccines: a review of preclinical and clinical data. Rev Med Virol 18:217–231. PubMed

Nalca A, Zumbrun EE (2010) ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile. Drug Des Devel Ther 4:71–79. PubMed PMC

Frey SE, Newman FK, Kennedy JS, Sobek V, Ennis FA, et al. (2007) Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge. Vaccine 25:8562–8573. PubMed PMC

von Krempelhuber A, Vollmar J, Pokorny R, Rapp P, Wulff N, et al. (2010) A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine 28:1209–1216. PubMed PMC

Stittelaar KJ, van Amerongen G, Kondova I, Kuiken T, van Lavieren RF, et al. (2005) Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J Virol 79:7845–7851. PubMed PMC

Townsend MB, Keckler MS, Patel N, Davies DH, Felgner P, et al. (2012) Humoral Immunity to Smallpox Vaccines and Monkeypox virus Challenge; Proteomic Assessment and Clinical Correlations. J Virol doi:101128/JVI02089-12. PubMed PMC

Davies DH, Wyatt LS, Newman FK, Earl PL, Chun S, et al. (2008) Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax. J Virol 82:652–663. PubMed PMC

Arness MK, Eckart RE, Love SS, Atwood JE, Wells TS, et al. (2004) Myopericarditis following smallpox vaccination. Am J Epidemiol 160:642–651. PubMed

Marcinak J, Vora S, Weber S, Thomson K, Garcia-Houchins S, et al. (2007) Household transmission of vaccinia virus from contact with a military smallpox vaccine–Illinois and Indiana, 2007. MMWR Morb Mortal Wkly Rep 56:478–481. PubMed

Wertheimer ER, Olive DS, Brundage JF, Clark LL (2012) Contact transmission of vaccinia virus from smallpox vaccinees in the United States, 2003-2011. Vaccine 30:985–988. PubMed

Neff JM, Lane JM, Fulginiti VA, Henderson DA (2002) Contact vaccinia–transmission of vaccinia from smallpox vaccination. Jama 288:1901–1905. PubMed

Becker Y (2003) Vaccinia virus pathogenicity in atopic dermatitis is caused by allergen-induced immune response that prevents the antiviral cellular and humoral immunity. Virus Genes 27:269–282. PubMed

Leung DY, Bieber T (2003) Atopic dermatitis. Lancet 361:151–160. PubMed

De Benedetto A, Agnihothri R, McGirt LY, Bankova LG, Beck LA (2009) Atopic dermatitis: a disease caused by innate immune defects? J Invest Dermatol 129:14–30. PubMed

Kawakami T, Ando T, Kimura M, Wilson BS, Kawakami Y (2009) Mast cells in atopic dermatitis. Curr Opin Immunol 21:666–678. PubMed PMC

Gutermuth J, Ollert M, Ring J, Behrendt H, Jakob T (2004) Mouse models of atopic eczema critically evaluated. Int Arch Allergy Immunol 135:262–276. PubMed

Shiohara T, Hayakawa J, Mizukawa Y (2004) Animal models for atopic dermatitis: are they relevant to human disease? J Dermatol Sci 36:1–9. PubMed

Vestergaard C, Yoneyama H, Matsushima K (2000) The NC/Nga mouse: a model for atopic dermatitis. Mol Med Today 6:209–210. PubMed

Spergel JM, Mizoguchi E, Brewer JP, Martin TR, Bhan AK, et al. (1998) Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice. J Clin Invest 101:1614–1622. PubMed PMC

Jin H, He R, Oyoshi M, Geha RS (2009) Animal models of atopic dermatitis. J Invest Dermatol 129:31–40. PubMed PMC

Watanabe H, Numata K, Ito T, Takagi K, Matsukawa A (2004) Innate immune response in Th1- and Th2-dominant mouse strains. Shock 22:460–466. PubMed

Kawakami Y, Tomimori Y, Yumoto K, Hasegawa S, Ando T, et al. (2009) Inhibition of NK cell activity by IL-17 allows vaccinia virus to induce severe skin lesions in a mouse model of eczema vaccinatum. J Exp Med 206:1219–1225. PubMed PMC

Oyoshi MK, Elkhal A, Kumar L, Scott JE, Koduru S, et al. (2009) Vaccinia virus inoculation in sites of allergic skin inflammation elicits a vigorous cutaneous IL-17 response. Proc Natl Acad Sci U S A 106:14954–14959. PubMed PMC

Scott JE, ElKhal A, Freyschmidt EJ, MacArthur DH, McDonald D, et al. (2007) Impaired immune response to vaccinia virus inoculated at the site of cutaneous allergic inflammation. J Allergy Clin Immunol 120:1382–1388. PubMed

Meseda CA, Garcia AD, Kumar A, Mayer AE, Manischewitz J, et al. (2005) Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model. Virology 339:164–175. PubMed

Nemeckova S, Hainz P, Otahal P, Gabriel P, Sroller V, et al. (2001) Early gene expression of vaccinia virus strains replicating (Praha) and non-replicating (modified vaccinia virus strain Ankara, MVA) in mammalian cells. Acta Virol 45:243–247. PubMed

Kutinova L, Ludvikova V, Simonova V, Otavova M, Krystofova J, et al. (1995) Search for optimal parent for recombinant vaccinia virus vaccines. Study of three vaccinia virus vaccinal strains and several virus lines derived from them. Vaccine 13:487–493. PubMed

Kutinova L, Ludvikova V, Krystofova J, Otavova M, Simonova V, et al. (1996) Influence of the parental virus strain on the virulence and immunogenicity of recombinant vaccinia viruses expressing HBV preS2-S protein or VZV glycoprotein I. Vaccine 14:1045–1052. PubMed

Liskova J, Knitlova J, Honner R, Melkova Z (2011) Apoptosis and necrosis in vaccinia virus-infected HeLa G and BSC-40 cells. Virus Res 160:40–50. PubMed

Kalbacova M, Spisakova M, Liskova J, Melkova Z (2008) Lytic infection with vaccinia virus activates caspases in a Bcl-2-inhibitable manner. Virus Res 135:53–63. PubMed

Joklik WK (1962) The purification fo four strains of poxvirus. Virology 18:9–18. PubMed

Barchichat S, Katz E (2002) Immunization of rabbits with a modified vaccinia Ankara recombinant virus bearing the HIV envelope antigen on its outer membrane. Virus Res 90:243–251. PubMed

Humlova Z, Vokurka M, Esteban M, Melkova Z (2002) Vaccinia virus induces apoptosis of infected macrophages. J Gen Virol 83:2821–2832. PubMed

Combadiere B, Boissonnas A, Carcelain G, Lefranc E, Samri A, et al. (2004) Distinct time effects of vaccination on long-term proliferative and IFN-gamma-producing T cell memory to smallpox in humans. J Exp Med 199:1585–1593. PubMed PMC

Kawakami Y, Yumoto K, Kawakami T (2007) An improved mouse model of atopic dermatitis and suppression of skin lesions by an inhibitor of Tec family kinases. Allergol Int 56:403–409. PubMed

Frey SE, Couch RB, Tacket CO, Treanor JJ, Wolff M, et al. (2002) Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med 346:1265–1274. PubMed

Matsumoto M, Ra C, Kawamoto K, Sato H, Itakura A, et al. (1999) IgE hyperproduction through enhanced tyrosine phosphorylation of Janus kinase 3 in NC/Nga mice, a model for human atopic dermatitis. J Immunol 162:1056–1063. PubMed

Suto H, Matsuda H, Mitsuishi K, Hira K, Uchida T, et al. (1999) NC/Nga mice: a mouse model for atopic dermatitis. Int Arch Allergy Immunol 120 Suppl 170–75. PubMed

Yagi R, Nagai H, Iigo Y, Akimoto T, Arai T, et al. (2002) Development of atopic dermatitis-like skin lesions in STAT6-deficient NC/Nga mice. J Immunol 168:2020–2027. PubMed

Mamessier E, Botturi K, Vervloet D, Magnan A (2005) [T regulatory lymphocytes, atopy and asthma: a new concept in three dimensions]. Rev Mal Respir 22:305–311. PubMed

Anderson E, Pierre-Louis WS, Wong CJ, Lary JW, Cole JL (2011) Heparin activates PKR by inducing dimerization. J Mol Biol 413:973–984. PubMed PMC

Rager KJ, Langland JO, Jacobs BL, Proud D, Marsh DG, et al. (1998) Activation of antiviral protein kinase leads to immunoglobulin E class switching in human B cells. J Virol 72:1171–1176. PubMed PMC

Davies MV, Chang HW, Jacobs BL, Kaufman RJ (1993) The E3L and K3L vaccinia virus gene products stimulate translation through inhibition of the double-stranded RNA-dependent protein kinase by different mechanisms. J Virol 67:1688–1692. PubMed PMC

Williams BR (1999) PKR; a sentinel kinase for cellular stress. Oncogene 18:6112–6120. PubMed

Baixeras E, Cebrian A, Albar JP, Salas J, Martinez AC, et al. (1998) Vaccinia virus-induced apoptosis in immature B lymphocytes: role of cellular Bcl-2. Virus Res 58:107–113. PubMed

Engelmayer J, Larsson M, Subklewe M, Chahroudi A, Cox WI, et al. (1999) Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. J Immunol 163:6762–6768. PubMed

Haga IR, Bowie AG (2005) Evasion of innate immunity by vaccinia virus. Parasitology 130 Suppl: S11–25 PubMed

Martin RM, Brady JL, Lew AM (1998) The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice. J Immunol Methods 212:187–192. PubMed

Oyoshi MK, Ramesh N, Geha RS (2011) Vaccinia Ig ameliorates eczema vaccinatum in a murine model of atopic dermatitis. J Invest Dermatol 132:1299–1301. PubMed PMC

von Sonnenburg F, Perona P, Darsow U, Ring J, von Krempelhuber A, et al. (2014) Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis. Vaccine 32:5696–5702. PubMed

Guzman E, Cubillos-Zapata C, Cottingham MG, Gilbert SC, Prentice H, et al. (2012) Modified vaccinia virus Ankara-based vaccine vectors induce apoptosis in dendritic cells draining from the skin via both the extrinsic and intrinsic caspase pathways, preventing efficient antigen presentation. J Virol 86:5452–5466. PubMed PMC

Perdiguero B, Gomez CE, Najera JL, Sorzano CO, Delaloye J, et al. (2012) Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens. PLoS One 7:e48524. PubMed PMC

Reed JL, Scott DE, Bray M (2012) Eczema vaccinatum. Clin Infect Dis 54:832–840. PubMed

Stahlberg A, Hakansson J, Xian X, Semb H, Kubista M. (2004) Properties of the reverse transcription reaction in mRNA quantification. Clin Chem 50:509–515. PubMed

Miljkovic Z, Momcilovic M, Miljkovic D, Mostarica-Stojkovic M (2008) Methylprednisolone inhibits IFN-gamma and IL-17 expression and production by cells infiltrating central nervous system in experimental autoimmune encephalomyelitis. J Neuroinflammation 6:37. PubMed PMC

Vaccinia Virus Expressing Interferon Regulatory Factor 3 Induces Higher Protective Immune Responses against Lethal Poxvirus Challenge in Atopic Organism